Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356544 | 0.89 | HTR1A (0.48) | HTR1ASLC6A4HTR7KCNH2ADRA2A | |
| SCHEMBL9370962 | 0.88 | HTR1A (0.49) | HTR1ASLC6A4HTR7KCNH2ADRA2A | |
| Hydrochloric Acid SCHEMBL9371205 | 0.87 | HTR1A (0.40) | HTR1ASLC6A4HTR7KCNH2 | |
| SCHEMBL6362588 | 0.86 | HTR1A (0.49) | HTR1ASLC6A4HTR7KCNH2ADRA2A | |
| SCHEMBL8978707 | 0.86 | HTR1A (0.46) | HTR1ASLC6A4HTR7KCNH2ADRA2A | |
| SCHEMBL6362303 | 0.85 | HTR1D (0.53) | HTR1ASLC6A4HTR7KCNH2 | |
| SCHEMBL6358101 | 0.85 | HTR1A (0.49) | HTR1ASLC6A4HTR7KCNH2 | |
| SCHEMBL4346029 | 0.85 | HTR1A (0.48) | HTR1ASLC6A4HTR7KCNH2ADRA2A | |
| SCHEMBL8978745 | 0.83 | HTR1A (0.47) | HTR1ASLC6A4HTR7KCNH2ADRA2A | |
| SCHEMBL8978735 | 0.83 | HTR1A (0.47) | HTR1ASLC6A4HTR7KCNH2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | claimed |
| US-20050095286-A1 | Extended release compositions | FABRE KRAMER PHARMACEUTICALS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095286-A1 | Extended release compositions | PDE3A, GIPR, PDE7A | HTR1A 22/4885SLC6A4 167/4885HTR7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.